Mydecine Innovations Group Inc. (MYCOF) Corporate Media Kit

Mydecine Innovations Group Inc. (MYCOF)

InvestorBrandNetwork (IBN) 8033 Sunset Blvd. Suite 1037 Los Angeles, CA 90046 (310) 299-1717 Mydecine Innovations Group Inc. 1250 S. Parker Rd., Suite A Denver, CO 80231 (720) 277-9879

Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company developing innovative first- and second-generation novel therapeutics to treat unmet needs in mental health and addiction disorders. Focusing on psychedelic compounds and other novel molecules with therapeutic potential, the Mydecine business model combines their world-class team and drug development infrastructure with advanced technology, clinical trials and data outcomes. Founded in 2020 to address a significant lack of innovation in the mental health treatment environment, Mydecine currently is pursuing indications such as addiction, PTSD and anxiety. By collaborating with some of the world’s foremost authorities, the company aims to responsibly fast track the development of novel medicines to provide patients with safer and more effective treatment options. Mydecine’s leadership team combines vast experience in drug development, medicinal chemistry, clinical trials, and mental health and addiction disorders. Supported by a top-notch medical and scientific advisory board of global experts, the company is progressing a robust R&D pipeline of psychedelic-derived therapeutics, novel compounds and controlled drug delivery systems.

Research and Technology Mydecine’s research strategy hinges on identifying and developing novel psychedelic and non-psychedelic molecules for medical use. Using molecules found in nature as building blocks to produce second-generation drugs, the company’s R&D efforts focus on compounds that may enable safer, more effective treatments for patients, as well as providing clinicians with better management of dosage and drug behavior. Through an exclusive partnership with Applied Pharmaceutical Innovation and the University of Alberta, Mydecine leverages the benefits of artificial intelligence and machine learning (AI/ML). The university’s faculty of pharmacologists is currently ranked in the top 15 in the world for pharmaceutical drug discovery, and top three in the world for artificial intelligence. Using AI/ML, the team can screen billions of compounds rapidly without the need to produce them, and can immediately collect data on viable drug candidates prior to further investment in development. By centering drug discovery efforts on AI/ML, Mydecine is positioned to discover drug enhancements cost effectively and efficiently. The University of Alberta partnership brings an extraordinarily strong depth of experience in pharmaceutical and natural products chemistry, and also allows the company to complete all production for its clinical trials. Mydecine’s pipeline currently consists of drug candidates that provide various enhancements such as improved delivery mechanisms, safety, controllability, stability and shelf-life. These drug candidates are part of psychedelic-assisted therapy programs and are in clinical trials or pre-trial stages as potential treatments for smoking cessation and PTSD. Mydecine’s clinical trial highlights include a five-year research agreement with Johns Hopkins University, one of the most experienced academic institutions in conducting clinical research related to psychedelic therapies.

The Mindleap Platform is the first international virtual health platform to include psychedelic integration. As a wholly-owned subsidiary of Mydecine, Mindleap has access to world-class research personnel who contribute directly to the build-out and improvement of this AI-powered dashboard, designed to help optimize one’s mental healing journey. Mindleap provides features for introduction and post-care integration that include fact-based education, 1:1 video coaching, trustworthy content, wellness guidance, and even a built-in health journal. Additionally, the technology enables healthcare professionals to remotely administer the majority of their protocol for psychedelic-assisted treatment, enhancing accessibility and scalability. Mindleap is also fully HIPAA and PIPEDA compliant, so everything is private and discreet. Mindleap currently has thousands of downloads and hundreds of licensed mental health coaches that can generate their own part-time or full-time income directly through the platform. As subscriber growth continues, Mindleap will expand its development team and broaden connections with leading healthcare organizations, practitioners, and researchers through its clinic program. The platform is available on iOS and Android, with an expanded web version on the way.

Market Considerations Amid a growing body of clinical evidence demonstrating the therapeutic benefits of psychedelics as medicine, Mydecine is positioning for opportunity across growing sectors. The global smoking cessation market is expected to increase at a CAGR of 16.9% to reach nearly $64 billion by 2026. The psychedelic therapeutics market, which is in its very early stages, shows wide-ranging estimates for the current value and expected growth. Market forecasts range from $6.5 billion by 2030 to more than $69 billion as soon as 2025, growing at CAGRs from 8.2% and 15%, respectively.

Investor Overview DPortfolio includes a robust line of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates DExclusive partnership with Applied Pharmaceutical Innovation provides access to a world-class, end-to-end drug development infrastructure under one roof DTeam of highly experienced chemists, doctors and scientists specialized in pharmaceutical chemistry, natural products chemistry and drug development DFive-year master collaboration research agreement with Johns Hopkins University to research novel psychedelic therapies for mental health and addiction disorders DResearch out of Johns Hopkins has shown promising efficacy data using psilocybin as a smoking cessation treatment with an 80% abstinence rate at six months DOnly industry sponsored clinical trial assessing psilocybin for smoking cessation DLead drug candidate, MYCO-001, is being supplied for a multi-site NIDA (National Institute on Drug Abuse) grant-funded smoking cessation study, marking the first time in over 50 years that the U.S. government has funded a study of a psychedelic compound

Leadership Team Joshua Bartch Chief Executive Officer and Chairman Mr. Bartch is an experienced entrepreneur. He co-founded and founded the Denver-based dispensary, Doctors Order’s, in 2009. He later founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Mr. Bartch co-founded, the most significant and sophisticated legal cannabis wholesale platform in the United States. Mr. Bartch took successful exits from, Doctor’s Orders and Dr. Rakesh Jetly, OMM, CD, MD, FRCPC Chief Medical Officer Dr. Jetly is the former chief of psychiatry for the Canadian Armed Forces and retired in 2021 as a colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon deploying on missions in Rwanda and the Middle East. He spent his final 20 years as a psychiatrist deploying twice and leading mental health programs in Afghanistan. Dr. Jetly maintains academic appointments at Dalhousie University and the University of Ottawa. He is the inaugural chair of the CF Brigadier Jonathan C. Meakins CBE, RCMAC, chair in Military Mental Health at the Royal Ottawa Hospital. During his career, Dr. Jetly has led initiatives within Canada and NATO to better understand and innovate solutions in the mental health field. He has published extensively on topics such as PTSD, suicide, leveraging technology in mental health and occupational psychiatry.

Robert Roscow Chief Scientific Officer As an experienced geneticist, Mr. Roscow has spent his academic and professional career identifying valuable and unique medicinal molecules found in nature. He holds both master’s and bachelor’s degrees in biology. Prior to joining Mydecine, Mr. Roscow was director of genetics at Victory Hemp Foods and also at ebbu, which was acquired as a subsidiary of Canopy Growth Corporation, the largest cannabis company in the world. At ebbu, Mr. Roscow ran the world’s first cannabis genetic editing laboratory. He has leveraged an expertise in genomics, evolution and molecular biology to identify novel molecules and advance their use in a pharmacological context. His work has resulted in multiple patent filings and accolades in a variety of scientific and popular publications. Damon Michaels Chief Operating Officer Mr. Michaels previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as general manager for ebbu, a top multi-platform cannabinoid research and technology firm. By 2018, ebbu was the cutting-edge leader in cannabinoid science and was acquired for CAD$429 million by Canopy Growth Corporation, the largest cannabis company in the world. Mr. Michaels has held executive roles with multiple large brands throughout the cannabis vertical. He also served on the business development team for a Google Ventures company, developed a national snowboard brand and was one of four entrepreneurs who created Colorado’s first-ever glass recycling company.

For more information InvestorBrandNetwork (IBN) 8033 Sunset Blvd. Suite 1037 Los Angeles, CA 90046 (310) 299-1717 Please read our full disclaimer: © 2017-2022 InvestorBrandNetwork (IBN). All rights reserved. Created September 2020